FDA approves Zepbound® (tirzepatide) as the first and only …
INDIANAPOLIS, Dec. 20, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound ® (tirzepatide) as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. 1 Zepbound may help adults with moderate-to-severe ...
GLP-1 Zepbound Is Approved As First Drug For Sleep Apnea - U.S. News …
5 days ago · Zepbound, which was first approved for weight management in November 2023, now offers new hope for those with obesity and obstructive sleep apnea, Eli Lilly reported.
Tirzepatide reduced sleep apnea severity by up ... - Eli Lilly and …
Apr 17, 2024 · Tirzepatide meaningfully improved sleep apnea symptoms in those with moderate-to-severe OSA and obesity with and without PAP therapy, and based on these results Lilly plans to submit these data for global regulatory reviews.
Eli Lilly’s Zepbound Becomes First FDA-Approved Drug Therapy for Sleep …
5 days ago · Sleep apnea, which affects an estimated 25 million adults in the U.S., gives Lilly the opportunity to add another indication with blockbuster potential. More applications could be coming for the drug.
FDA Approves First Medication for Obstructive Sleep Apnea
Dec 20, 2024 · “This is a major step forward for patients with obstructive sleep apnea.” OSA occurs when a person’s upper airway becomes blocked, causing pauses in breathing during sleep.
FDA approves Eli Lilly’s obesity medication for obstructive sleep apnea
Dec 20, 2024 · The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe obstructive sleep apnea for people with obesity -- the first medication approved for the condition.
The FDA just approved Eli Lilly's Zepbound for sleep apnea — …
Dec 20, 2024 · Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the U.S. Food and Drug Administration (FDA) as the first prescription drug to help alleviate moderate ...
Eli Lilly expects FDA call on Zepbound for sleep apnea in near term
Jun 21, 2024 · Eli Lilly said it applied for U.S. approval of its weight loss drug Zepbound for the treatment of the most common sleep-related breathing disorder and expects regulators to make a decision as...
Tirzepatide reduced sleep apnea severity by up to nearly two …
Apr 17, 2024 · Eli Lilly and Company (NYSE: LLY) today announced positive topline results of the SURMOUNT-OSA phase 3 clinical trials that showed tirzepatide injection (10 mg or 15 mg) significantly reduced...
FDA approves Eli Lilly’s weight loss drug Zepbound for sleep apnea ...
Dec 20, 2024 · The weekly injection is now the first drug treatment option cleared for patients with obesity and moderate-to-severe obstructive sleep apnea, which refers to breathing interrupted...
- Some results have been removed